Immune checkpoint inhibitors targeting the PD-1/PD-L1 axis, such as pembrolizumab and nivolumab, have shown promise in reactivating the immune system to recognize and destroy tumor cells in various cancers. This evidence concerns the gene CD274 and cancer.